Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Investigation launched into ADMA Biologics over alleged misleading revenue claims causing stock plunge
ADMA
$8.86
+$0.18 +2.07%

Investigation launched into ADMA Biologics over alleged misleading revenue claims causing stock plunge

Market News
15 Apr 2026
PRNewsWire
View Source
Bearish
pluang ai news

Rosen Law Firm has announced an investigation into ADMA Biologics following allegations that the company issued misleading business information to inflate revenue, causing its stock to drop 16.6% on March 24, 2026. The investigation follows a report by short seller Culper Research accusing ADMA Biologics of channel stuffing to boost revenue figures. Investors who purchased ADMA securities may be eligible to join a class action lawsuit seeking compensation without upfront fees. The Rosen Law Firm is preparing to represent affected shareholders and encourages investors to contact them for participation details.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App